Vitamin B12 supplementation in end stage renal diseases : A systematic review by Amini, Maryam et al.
Original Article
http://mjiri.iums.ac.ir Medical Journal of the Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
____________________________________________________________________________________________________________________
1. PhD in Nutrition, Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences,
Tehran, Iran. aminmar67@yahoo.com
2. (Corresponding author) PhD, MSPH in Nutrition, Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Teh-
ran University of Medical Sciences, Tehran, Iran. k27666@yahoo.com
3. MD, PhD. in Epidemiology, Associate Professor of Clinical Epidemiology, Endocrine Research Center (Firouzgar),  Institute of Endocrinolo-
gy & Metabolism, Iran University of Medical Sciences, Tehran, Iran. baradaran.hr@iums.ac.ir
4. MSc. in Medical Library & Information Science, Endocrinology and Metabolism Research Institute, Iran University of Medical Sciences,
Tehran, Iran. rashaatlasi@gmail.com
Vitamin B12 supplementation in end stage renal diseases: a sys-
tematic review
Maryam Amini1, Maryam Khosravi2, Hamid Reza Baradaran3, Rasha Atlasi4
Received: 29 November 2013 Accepted: 3 May 2014 Published: 27 January 2015
Abstract
Background: Hyperhomocysteinemia is a risk factor for cardiovascular disease particularly in patients with
end stage renal disease (ESRD). Vitamin B12 supplementation on its own still remains as a controversial issue
for clinicians in decreasing the level of homcysteine in this group of patients.
Methods: Using all randomized controlled trials (RCTs), clinical trials and pre-post-trial studies found during
January 1999 to March 2014, we conducted a systematic review which assessed the effects of vitamin B12 in
decreasing homocysteine levels in patients with ESRD.
Results: The findings of this study revealed that, overall, the greatest effect of B12 supplementation on de-
creasing homocysteine levels in patients with ESRDs occurred when it was combined with folate supplementa-
tion. It was also demonstrated that injection treatments might be more beneficial than oral intake treatments.
Conclusion: More rigorous studies are needed to draw a firm conclusion about B12 therapy and the level of
homocyteine in patients with ESRD.
Keywords: Homocysteine, Kidney Failure, Vitamin B12, Hemodialysis, Kidney, Amino Acids, Renal Failure,
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Introduction
Hyperhomocysteinemia is an important
risk factor for cardiovascular disease (1).
Homocysteine is a nonessential amino acid,
and a metabolite for methionine metabo-
lism. It has two fates: remethylation to me-
thionine which is catalyzed by the vitamin
B12 dependent enzyme, methionine synthe-
tase, and transsulphuration to cystathionine,
and then into cysteine. The two essential
substances in the remethylation pathway
are vitamin B12, as a cofactor, and folate as
a substrate. Vitamin B6 is another crucial
cofactor for transsulphuration of homocys-
teine to cystathionine (2). Many of hemodi-
alysis patients are B12 depleted (3). Dialy-
sis patients usually have poor nutritional
intake, predisposing them to B12 deficien-
cy (4). Moreover, food sources of vitamin
B12 contain high concentrations of electro-
lytes which are dangerous for dialysis pa-
tients, and limit them to foods with low vit-
amin B12 content. In addition, B12 is a typ-
ical middle-sized chemical molecule to be
cleared with new high-flux dialyzers (3).
Therefore, plasma total homocysteine
(tHcy) concentration is noticeably in-
creased in end-stage renal disease (ESRD)
(5). Furthermore, comparing to patients
with normal renal function, the prevalence
of hyperhomocysteinemia and the resulting
death caused by atherosclerotic vascular
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disease are substantially greater in ESRD
patients (6). Hcy-lowering therapy is an
effective approach for hyperhomocyste-
inemia therapy of ESRD patients (7-9).
However, it is controversial whether cobal-
amin supplementation alone could be use-
ful in lowering the tHcy concentration in
these patients (10). Focusing on this con-
troversy, we conducted a systematic review
to assess the effects of vitamin B12 sup-
plementation alone on tHcy concentration
in ESRD patients.
Methods
Search Strategy
We found no systematic review or meta-
analysis on this subject; therefore, we
searched all English and Persian medical
literature published from January 1999 to
March 2014 in PubMed, Google Scholar,
Ovid, Cochrane Library, EMBASE, CI-
NAHL, Springer, Proquest, Scopus, Web of
Science, Science Direct, SID, Iranmedex
and Magiran databases.
The main search key words were as fol-
lows: ‘‘vitamin B12’’ AND ‘‘homocyste-
ine’’ AND ‘‘End Stage Renal Disease’’
with their synonyms, related words and
Medical Subject Headings (MeSH) terms.
The search strategy used in the PubMed
database can be found in Appendix 1.
A total of 1964 articles were collected, of
which 18 were duplicates. Titles of the re-
maining articles were reviewed for their
relevance to the homocysteine lowering
effect of vitamin B12 in end-stage renal
disease. If the articles were potentially rel-
evant, then their full texts were retrieved. A
further 1928 articles were excluded due to
failing to meet the eligibility criteria. After
reading the full text of the articles, 12 were
excluded because in those studies vitamin
B12 was not administered alone. All the
titles and abstracts which were derived
from the searches were extracted by a re-
viewer. In the event that the reviewer de-
termined that an article did not meet the
eligibility criteria, then the article would
have been rejected on initial screening. An
evaluation of the full texts was conducted
by a review team. Two reviewers evaluated
the full articles separately.
Fig.. 1. Flowchart of the Procedure used to Select the Relevant Articles
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Any disagreements between the reviewers
were resolved by discussion until consen-
sus was reached.
Inclusion Criteria
Randomized controlled trials (RCTs),
clinical trials and pre-post-trials were se-
lected for this systematic review. The focus
was on dialysis patients with end-stage re-
nal disease. Figure 1 demonstrates the pro-
cedure applied to select the relevant arti-
cles.
Results
Only 6 out of the total of 1964 articles
were eligible for the systematic review.
Most of these studies were trials (RCTs,
cross over and prospective), and only one
study was quasi-experimental (pre-post-
treatment) (Table 1). These studies were
heterogeneous with respect to the following
factors: type of administration (oral or in-
travenous), chemical construction of B12
(hydroxycobalamin, methycobalamin, cya-
nocobalamin or not defined), duration of
intervention, period of outcome assessment,
study design and quality (Table 1). There-
Table 1. Methodological Description of the Included Studies
Author/Year/
Location
Sample
size
Type of
Study
Intervention/Comparison
(Study Arms)
Study Exclusion/Inclusion
Criteria
Comments
Chiu,Y.W.2009,
Taiwan [11]
75 RCT I: Received vitamin B12
1mg/week intravenously
for 3 months
C: Received folinic acid
3mg/week intravenously
for 3 months
Combination group:
Received intravenous
supplementation with
both agents weekly for 3
months
Inclusion criteria:
-Hemodialysis patients
without any acute illness
Masking was
NOT reported.
Method of ran-
dom allocation
was not men-
tioned
Hemodialysis
period was not
similar in dif-
ferent arms of
the study.
Pastore, A. 2006,
Italy [10]
200 RCT(cross
over)
Group 1: Based on 3
genotypes CC, CT and
TT, Initially received
cobalamin 1250 µg per
week for 2 months, oral-
ly, then received 15 mg
folic acid daily for 8
weeks, orally.
Group 2: Initially re-
ceived folic acid 2
months, then B12 for
next 2 months.
Exclusion criteria:
-Receiving folic acid
and/or vitamin B12 before
the study
Inclusion criteria:
-All patients had baseline
tHcy concentrations >20
µmol/L
-All had been undergoing
HD for at least 3 months
and duration of 4 h each
time.
Loss to follow-
up was as high
as 52% but not
considered in
the analysis
(Itention to treat
analysis).
Study was sin-
gle-blinded.
Polkinghorne,2003,
Austrailia [2]
28 RCT I: Received hydroxyco-
balamin 1 mg per month
for 3 months, adminis-
tered by intramascular
injection.
C: Received placebo
(saline) for 3 months
Exclusion criteria:
-Current high dose folic
acid supplementa-
tion(>5mg/w)
-Vitamin B12 deficiency
-Past medical history of
cancer or inflammatory
bowel disease
- Recent return to dialysis
after transplantation, im-
minent live donor trans-
plant
-Current use of antifolate
or anti convulsant medica-
tion
Inclusion criteria:
-Age>18y
- Hemodialysis at least 1
month prior to recruitment
The participants
and the investi-
gator were
blind; however,
nurses who
injected pacebo
or B12 were not
blind.
Power is not
large enough to
show small
changes (less
than 30%).
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fore, it was not appropriate to synthesize
the results for a meta-analysis.
The findings of the trials and quasi-
experimental studies are summarized in
Tables 2 and 3, respectively.
Six interventions administered B12 alone.
All 5 selected trials applied B12 in at least
one study arm (2, 10-13).
There were four groups in Chiu’s study
(Table 1) (11). In one group, B12 was in-
jected alone while all other three groups
had taken folate in advance. In the final as-
sessment, the blood levels of tHcy were
decreased significantly in all groups, in-
cluding the group which received B12
alone. However, the combination group
showed an added effect, indicating the syn-
ergistic role of folate and B12 in tHcy low-
ering.
In Polkinghorne’s trial (2), one mg vita-
min B12 was administered intramuscularly
in one group to determine whether B12,
without the effect of folic acid, could lower
the homocysteine (Table 1). However, in
their study, the tHcy concentration was not
different in the two groups at the end of the
intervention. Therefore, they concluded that
there was no decrease in tHcy levels within
the three months of intramuscular admin-
istration of B12 alone.
Arnadottir (13) held a trial on folate-
replete hemodialysis patients. The treat-
ment group received vitamin B12 tablets
(orally) at a dose of 2 mg 3 times a week
for 6 weeks while the control group re-
ceived no treatment. At the end of the study
period, plasma tHcy concentration de-
creased significantly in both groups with no
difference between them.
There were four study arms in Tri-
marchi’s study (12). One group received
only 500 µg Me-Cobalamin twice a week,
but at the end of the study, no significant
changes of tHcy level was observed in this
group, indicating the minor role of B12 in
tHcy level correction.
The role of genotype in the reduction of
tHcy was discussed in two different studies.
In a cross-over design, Pastore et al. (10)
compared the effect of folate and B12 sup-
plementation on Hcy (homocysteine) re-
duction. Consecutive vitamin therapy de-
Table 1. Continued
Arnadottir,M.,2003,
Sweden [13]
28 RCT I: Received 2mg B12 tablets 3
times a week for 6 weeks
orally
C: Received no such treat-
ment
Nothing men-
tioned
Participants or
the researchers
were not blind;
control group
did not take
placebo.
Trimarchi H.2002
Argentina [12]
62 Prospective
Randomized
trial
I: Group A received
methylcobalamin 500 micro
gram twice/week plus folic
acid 10 mg/day; group B re-
ceived folic acid 10 mg/day
alone; group C received no
vitamin supplementation, and
group D was on Methylcobal-
amin 500 micro gram
twice/week alone.
C: folic acid 10 mg/day alone;
no vitamin supplementation
for 4 months postdialysis
Exclusion crite-
ria:
-Previous vitamin
supplementation
Inclusion criteria:
-Patients between
19 and 86 y
-Requiring HD
for at least 5
months
Randomization
and blindness
was not de-
scribed in the
study.
The study was
single-blinded.
Dierks, J.
1999
Norway [5]
14 Quasi-
experimental
Before: Cyanocobalamin,
1mg per week for 4 weeks
was administered in B12 defi-
cient participants Intravenous-
ly.
After: Changes of tHcy after
the injection of vitaminB12
was measured.
Inclusion criteria:
-low serum co-
balamin concen-
trations
The sample size
was too small.
Inclusion or
exclusion crite-
ria was not
defined exactly.
I: Intervention, C: Comparison
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creased tHcy in both groups and the de-
crease was genotype-dependant.
Only one study was conducted based on a
before/after design (5). In this study, the
effect of intravenous injection of cyanoco-
balamin was investigated in ESRD patients
with low serum cobalamin concentration.
Because tHcy concentration was unequal
among these studies at baseline, plasma
tHcy decreased significantly either with
normal or deficient levels of tHcy. In a
semi-experimental study, Dierkes et al. (5)
concluded that the tHcy lowering effect of
B12 may be due to the reduction of cellular
tHcy rather than renal clearance, and it is
influenced by genotype.
Discussion
To our knowledge, this was the first re-
view to focus on the role of B12 alone in
lowering tHcy in patients with end-stage
renal disease. A significant proportion of
ESRD patients have physiological vitamin
B12 deficiency. These patients may have a
defect in their ability to convert vitamin
B12 into its active form, hydroxylcobala-
min, which is needed for homocysteine me-
tabolism (14-15). In addition, transcobala-
Table 2. Findings of the Included Studies (Randomized Controlled Trials)
Author Control
mean dif-
ference
% of
change
for con-
trol
group
P value for
control group
Intervention
mean differ-
ence
% of change
for interven-
tion group
P value for
intervention
group
Difference
between
control
and other
groups
P value
Chiu 2009 3.3 ↓16.4 <0.05 5.9 ↓29.3 α <0.05 <0.005
7.8 ↓38.9 β <0.05 NS
Pastore
2006
Group
1 γ
CC 25.2 ↓35.39 0.021 5.3 ↓8.5 0.2 Not appli-
cable
CT 81.4 ↓60.97 <0.05 16.7 ↓19.4 0.41 Not appli-
cable
TT 221.7 ↓74.49 <0.01 101 ↓32.52 0.135 Not appli-
cable
Group
2 δ
CC 26 ↓45.61 0.2 17 ↓36.95 <0.05 Not appli-
cable
CT 44.3 ↓63.92 <0.05 12.1 ↓23.22 0.169 Not appli-
cable
TT 88.5 ↓42.24 0.237 -8.8 ↑11.62 0.497 Not appli-
cable
Polkinghorne
2003
-2 ↑8.22 - 2.01 ↓7.89 ε - 0.4
Arnadottir 2003 5 ↓23.15 <0.05 3.6 ↓17.3 κ <0.01 NS
Trimarchi 2002 -1.4 ↑5.4 NS 12.3 ↓54.6 λ 0.003 <0.001
8.7 ↓43.7 μ 0.012 <0.001
2.3 ↓8.6 ν NS NS
α: Vitamin B12 administered 1mg/week intravenously for 3 months
β:  IV supplementation with folinic acid 3mg plus B12 1mg intravenously for 3 months/week
γ : Initially received cobalamin 1250 µg per week for 2 months, orally, then received 15 mg folic acid daily for 8 weeks, orally.
δ : Initially received folic acid 2 months, then B12 for next 2 months
ε: Hydroxycobalamin 1 mg/month for 3 months admininstered by intramuscular injection
κ: B12 tablets 2mg, administered 3 times a week for 6 weeks orally
λ: Received methylcobalamin 500 micro gram twice/week plus folic acid 10 mg/day
μ: Received folic acid 10 mg/day alone
ν: Received methylcobalamin 500 micro gram twice/week alone
NS: Not significant
NA: Not Applicable
Table 3. Findings of the Included Quasi-Experimental Study
Author Defference between baseline
and final assessment (median)
% of change Difference between before
and after(P value )
Dierkes 1999 CC 13.2 ↓38.15 NS
CT,TT 12.2 ↓26.69 NS
All 11.4 ↓27.94 0.01
NS: Not significant
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min II, which is necessary for the entry of
vitamin B12 into tissues, may be impaired
in ESRD (6, 14-15). Therefore, tHcy con-
centration increases in patients with ESRD.
It is debatable whether vitamin B12 sup-
plementation alone could reduce tHcy con-
centration in these patients. Moreover, it is
reported that folate supplementation can
lower the high levels of homocysteine in
ESRD patients (16-18). However, it is not
clear whether vitamin B12 could reduce
homocysteine without the high-dose of fo-
lic acid. In the current review, all the in-
cluded studies administered B12 alone, but
with different approaches.
In Chiu’s study, the reduction of tHcy in
B12 group was significantly more than the
Folinic acid group (Table 2). It is also not-
ed that the combined supplementation was
the most effective method (11). In this
study, there was no significant difference
between the patients with respect to age,
sex, MTHFR C667T genotype, plasma lev-
els of folic acid, VitB12, or tHcy level at
baseline. However, the only difference
among the patients was the period of he-
modialysis at that time. Therefore, the tHcy
level of the vitamin B12 group might have
been affected by the difference in hemodi-
alysis duration (11).
In Polkinghorne’s trial (2), patients with
current high dose supplementation with fo-
late were not included in the study. The
levels of B12 and folate in serum were
normal in these patients, but the haemodi-
alysis period was in a very wide range; and
this may cause mixed results and could be
adjusted initially. Compared with another
study (20), the supplemental dose of B12 in
Polkinghorne’s study (2) appears to be too
low (1 mg/month vs. 2-3 mg/week) which
may have led to such a result.
Arnadottir et al. held a trial on folate-
replete hemodialysis patients (13). The
study samples were on hemodialysis for at
least 3 months and had all been receiving
folic acid in advance. However, the simul-
taneous decrease of serum homocysteine
concentration was not consistent in the con-
trol and intervention groups; this point was
not well described by the article (13). This
result may be due to the confounders which
were not considered by the researcher in
advance, which makes the result rather un-
reliable.
In Trimarchi’s study, the random alloca-
tion, blindness of patients and having a
control group were almost impeccable (12).
In Pastore’s study, the consecutive vita-
min therapy lowered tHcy in both groups,
and the decrease was genotype-dependant
(10). In Fodinger’s study, despite the role
of genotype and folate in the tHcy concen-
tration, B12 administration made no chang-
es in ESRD patients (20). The results of the
last two studies indicated that the effect of
B12 on tHcy should be measured in pa-
tients with normal serum folate. This find-
ing is inconsistent with that of the Dierk’s
study, in which the level of serum folate
was normal, but B12 level was low and
B12 supplementation lowered tHcy by 35%
(5). In a study by Trimarchi, the patients
received no supplementation in advance,
and B12 supplementation resulted in no
changes in the tHcys level (12).
Only one study was performed based on a
quasi-experimental design (5). In this
study, the intravenous injection of cyano-
cobalamin lowered the tHcy level in ESRD
patients with low serum cobalamin concen-
trations. The author suggested that the re-
duction of cellular tHcy was the cause, ra-
ther than the renal clearance, which is in-
fluenced by genotype. With respect to the
result of the study, some points should be
considered. First, the result was probably
due to the low baseline serum cobalamin in
patients. In other words, the correction of
B12 deficiency, rather than B12 supple-
mentation, was effective. Furthermore, ac-
cording to the article, sample size was too
small to represent a significant difference.
And finally, the study design could have
been more improved by having a control
group. One strong point of the study was
the inclusion of genotype. They indicated
that the reduction of homocysteine levels in
patients with CC genotype is much more
than in those with T allele (CT, TT). It
M. Amini, et al.
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seems that the essential role of cobalamin
in remethylation of tHcy was the reason
behind the simultaneous reduction of ho-
mocysteine and folate levels. They con-
cluded that folate is used as substrate and
this cycle is influenced by genotype (5).
Conclusion
In all the included studies, the design,
dosage of supplements, method of applica-
tion, status of other supplements and treat-
ments were different, and this makes the
final conclusion relatively difficult. It
seems that the maximum effect of B12
supplementation in ESRD patients is yield-
ed by injection, rather than oral intake. Fur-
thermore, the administration of pharmaco-
logic dosage of B12 in combination with
folate makes it more efficient. Conducting
future studies with randomized controlled
design, sufficient sample size and on pa-
tients with normal level of folate and B12 is
highly recommended to clarify the effect of
B12 supplementation on tHcy concentra-
tions in ESRD.
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Appendix-1
Search Strategy in PubMed:
("Vitamin B 12"[Mesh] OR "Vitamin B
12 Deficiency"[Mesh] OR "factor III, vita-
min B 12" [Supplementary Concept] OR
"Vitamin B Complex"[Mesh] OR "Vitamin
B Complex" [Pharmacological Action] OR
"Vitamin B Deficiency"[Mesh] OR (vita-
min AND ("b12" OR "b 12")) OR Cyano-
cobalamin OR Cobalamins OR Cobalamin
OR "HMQC" OR ("factor III" AND cor-
rinoid) OR "5-
hydroxybenzimidazolylcobamide" OR "5-
hydroxybenzimidazolylcobamid" OR "5
hydroxybenzimidazolylcobamide" OR "5
hydroxybenzimidazolylcobamid")
AND
("Hyperhomocysteinemia" [Mesh] OR
"Homocysteine"[Mesh] OR "Homocys-
tine"[Mesh] OR "Homocystinuria"[Mesh]
OR Hyperhomocysteinemias OR homo-
cystinuria OR homocysteine OR homocys-
tine OR "thcy" OR "hcy" OR "2-amino-4-
mercaptobutyric acid" OR "2 amino 4 mer-
captobutyric acid")
AND
("Kidney Failure, Chronic"[Mesh] OR
"Renal Dialysis"[Mesh] OR "Ure-
mia"[Mesh] OR "Renal Insufficien-
cy"[Mesh] OR "Renal Replacement Thera-
py"[Mesh] OR "Hemofiltration"[Mesh] OR
"Hemodiafiltration"[Mesh] OR "Ultrafiltra-
tion"[Mesh] OR "Kidneys, Artifi-
cial"[Mesh] OR ((Kidney OR RENAL)
AND (End-Stage OR End Stage OR failure
OR Insufficiencies OR Insufficiency OR
replacement OR artificial)) OR (Chronic
AND (Kidney OR RENAL) AND (Failure
OR Insufficiencies OR Insufficiency )) OR
ESRD OR ((Dialyses OR Dialysis) AND
(Renal OR Extracorporeal)) OR Hemodial-
ysis OR Hemodialyses OR Uremias OR
Uremia OR Hemofiltration OR Ultrafiltra-
tion OR Hemodiafiltration)
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